Lorenzo Erra, Ignacio Uriarte, Ana Colado, María Virginia Paolini, Gisela Seminario, Julieta Belén Fernández, Lorena Tau, Juliana Bernatowiez, Ileana Moreira, Sebastián Vishnopolska, Martín Rumbo, Chiara Cassarino, Gustavo Vijoditz, Ana Laura López, Renata Curciarello, Diego Rodríguez, Gastón Rizzo, Malena Ferreyra, Leila Romina Ferreyra Mufarregue, María Noel Badano, María Inés Pérez Millán, María Florencia Quiroga, Patricia Baré, Itatí Ibañez, Roberto Pozner, Mercedes Borge, Guillermo Docena, Liliana Bezrodnik, and María Belén Almejun
Patients with inborn errors of immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfizer vaccines, even though most of the data of humoral and cellular responses combination on available vaccines comes from trials conducted in healthy individuals. We aimed to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina. The study cohort included adults and pediatric IEI patients (n = 118) and age-matched healthy controls (HC) (n = 37). B cell response was evaluated by measuring IgG anti-spike/receptor binding domain (S/RBD) and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed with an alpha-S protein-expressing pseudo-virus assay. The T cell response was analyzed by IFN-γ secretion on S- or N-stimulated PBMC by ELISPOT and the frequency of S-specific circulating T follicular-helper cells (TFH) was evaluated by flow cytometry.No moderate/severe vaccine-associated adverse events were observed. Anti-S/RBD titers showed significant differences in both pediatric and adult IEI patients versus the age-matched HC cohort (p 0.05). Neutralizing antibodies were also significantly lower in the patient cohort than in age-matched HC (p 0.01). Positive S-specific IFN-γ response was observed in 84.5% of IEI patients and 82.1% presented S-specific TFH cells. Moderna vaccines, which were mainly administered in the pediatric population, elicited a stronger humoral response in IEI patients, both in antibody titer and neutralization capacity, but the cellular immune response was similar between vaccine platforms. No difference in humoral response was observed between vaccinated patients with and without previous SARS-CoV-2 infection.In conclusion, COVID-19 vaccines showed safety in IEI patients and, although immunogenicity was lower than HC, they showed specific anti-S/RBD IgG, neutralizing antibody titers, and T cell-dependent cellular immunity with IFN-γ secreting cells. These findings may guide the recommendation for a vaccination with all the available vaccines in IEI patients to prevent COVID-19 disease.